The Mafia of Pharma Pricing
The Federal Trade Commission report exposes health care conglomerates, particularly pharmacy benefit managers (PBMs), for inflating drug prices and manipulating the market. PBMs' practices contribute to rising healthcare costs and may lead to potential lawsuits.
Read original articleThe Federal Trade Commission released a report on the operations of health care conglomerates, likened to a mafia, manipulating drug prices. The report highlighted how pharmacy benefit managers (PBMs) inflated drug prices, leading to discrepancies between acquisition costs and what payers were charged. PBMs, acting as middlemen, redirected significant amounts of money to themselves, contributing to rising healthcare costs. The report indicated potential lawsuits against PBMs for high insulin prices, which could reshape the drug claims system and lower prices. Over the years, PBMs evolved from clerical agents to powerful entities influencing pharmaceutical pricing through consolidation and the legalization of price discrimination. This complex system involves multiple pricing benchmarks, rebates, and fees, making it challenging to determine actual drug costs. The interplay of price discrimination and consolidation has created a convoluted pricing environment, impacting patients, pharmacies, and insurers. The report sheds light on the opaque practices of PBMs and their significant role in shaping drug pricing dynamics, beyond the influence of traditional pharmaceutical companies.
Related
The Opaque Industry Inflating Prices for Prescription Drugs
Pharmacy Benefit Managers (PBMs) like CVS Health, Cigna, and UnitedHealth Group are criticized for increasing prescription drug costs in the US. Despite claims of cost reduction, PBMs allegedly steer towards expensive drugs, charge high markups, and prioritize financial gains over patients. Lawmakers are scrutinizing their practices for potential price inflation and anticompetitive behavior.
FICO and the Credit Bureau Cartel
Mortgage lenders are challenged by a cartel involving major credit bureaus and FICO, leading to rising costs for credit reports and scores. Director Chopra aims to regulate prices, gaining support from affected mortgage bankers.
200 people charged in $2.7B health care fraud crackdown
The Justice Department charged nearly 200 individuals in a $2.7 billion health care fraud crackdown. Cases involved scams targeting terminally ill patients, kickbacks for unnecessary treatments, and assets seized to prevent fleeing.
Pharma firms stash profits in Europe's tax havens
Pharma firms hide €580 billion in European tax havens, affecting drug prices and patient access. Companies exploit tax loopholes, impacting healthcare funding. Calls for transparency and accountability in the pharmaceutical industry arise.
Middlemen have outsized influence on drug prices due to market consolidation,FTC
The FTC highlights PBMs' dominance in U.S. drug pricing. Top PBMs control 79% of claims, raising concerns about cost inflation, lack of transparency, and conflicts of interest. Regulation and scrutiny are needed.
- Several commenters share personal experiences working within PBMs, highlighting unethical practices such as selling prescription data and managing kickbacks under the guise of "rebates".
- There is criticism of the inefficiency and complexity of PBM operations, often resulting from numerous mergers and acquisitions.
- Some commenters argue that the current private and regulated private industry models are inefficient and suggest that public ownership or alternative models might better serve the public good.
- Suggestions for reform include prohibiting integration between doctors and insurers with PBMs, repealing certain kickback exemptions, and requiring public filing of price lists to increase transparency.
- There is a general sentiment of frustration towards the pharmaceutical industry's pricing strategies, with some pointing out the significant role of intellectual property and patents in maintaining high drug prices.
- The company is launching a new service. We already sell customer drug-prescription data to drug companies, and the drug companies analyze this data to understand where/when/why/to-whom their drugs are being prescribed. Now we're going to help the drug companies advise doctors on where/when/why/to-whom they prescribe drugs.
- Sounds great. Where do we come in?
- The new service will act as a middleman, processing payments from drug companies to doctors.
- So, a service to manage kickbacks?
[Meeting room full of suits goes silent.]
- The payments aren't "kickbacks". They're "rebates".
- Is there a difference?
- Absolutely. [silence]
- So...what's the difference?
- Please be sure to only use the term "rebate" in all communications, especially email. Never use the term "kickback".
And that was pretty much it. The company processed prescriptions for pharmacies, then sold that data to drug companies, who in turn used that data to provide kickbacks to doctors for pushing their drugs over a competitor. And it was all legal, thanks to the lawyers and their select word usage. Oh, and I think we weren't supposed to use the term "middleman", either.
I worked in the "Innovation Lab", which had been designed to look like an ad agency's idea of Innovation -- brushed metal, Edison lightbulbs, that kind of thing. They'd bring clients through on tours to show off how much Innovation was going on. Meanwhile, I didn't really have that much to do, and no one seemed very concerned about that. Soon I realized I was also part of the decoration - a genuine Data Scientist, hard at work Innovating.
Our group produced approximately nothing. Our boss's boss was evaluated mostly based on how much he was able to sell people's medical data for.
Well.. I don't buy it. Access to drugs and efficient pricing and rationing (because that is what it is) is not working well. It's a massively distorted market.
The public good here would be better served by another model.
Even the "we need these prices to recover our massive sunk costs" part of the argument is bogus. Much good drug design and research is done on the tertiary education and research budget worldwide.
There is absolutely no single-process need to do drug IPR based models, the profit motive is not the only model.
I look to the modern mRNA drug emergence to lead to radical shake up in the cost of production of novel treatments. We're seeing some signs of this, along with other changes in drug models: injectable hypertension treatment is in test. Imagine the impact on the cost basis of a pill-per-day model!
They must be joking right?
There is no “price” for a drug, there are several prices - list, net, Medicaid, AMP, ASP.
So yes, while the list price for Gleevec has gone up, the actual price paid is very different.
It’s the same for insulin - the price that manufacturers have received has gone down 41% from 2014-2020, while the list price has gone up 140%.
https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEh...
If people want to really understand how it all works, I recommend the Drug Channel blog by Adam Fein. He does a great job of digging into details, pulling data and showing what prices are actually doing.
…
In 1987, Congress passed an exemption to a Medicare Anti-Kickback statute, which created a safe harbor for group buying entities to accept payment from drug manufacturers in the form of rebates, with certain guardrails in place.
…
PBMs get large secret rebates in return for allocating market shares…it’s virtually impossible to get any clear pricing on most drugs, because there is no one price.”
For a change the solutions seem simple:
1. Prohibit integration between doctors and insurers, on one hand, and pharmacies and pharmacy-benefit managers, on the other hand;
2. Repeal §§ d and f from the kickback exemptions [1]; and
3. Require public filing of insurers’, PBMs’ and pharmacies’ price lists. (Not disclosure: the binding price list is the public one.)
1. Health care providers are largely banned from importing drugs [2];
2. Medicare is largely banned from negotiating drug prices [3]
3. The VA was allowed under Obama to negotiate drug prices, something which was promised but never delivered for Medicare. The GAO shows this has reduced costs [4];
4. Pharma companies will tell you R&D is expensive. It is but it's the government paying for it. Basically all new novel drugs relied on public research funds [5];
5. Pharma companies generally spend more on marketing than R&D [6];
6. What R&D pharma companies actually do is typically patent extension [7].
The true "innovation" of capitalism is simply building layers and layers of enclosures.
[1]: https://en.wikipedia.org/wiki/Enclosure
[2]: https://journalofethics.ama-assn.org/article/what-should-pre...
[3]: https://www.healthaffairs.org/content/forefront/politics-med...
[4]: https://www.gao.gov/products/gao-21-111
[5]: https://www.cbc.ca/news/health/drugs-government-funded-scien...
[6]: https://marylandmatters.org/2024/01/19/report-finds-some-dru...
[7]: https://prospect.org/health/2023-06-06-how-big-pharma-rigged...
Big Pharma has been permitted to own PBMs.
https://www.ftc.gov/news-events/news/press-releases/1998/08/...
Societies can research, speculate, mitigate and regulate until the end of times for as long as the underlying fundamentals of the problems are never addressed.
If you have insurance with a yearly out of pocket max of say $8,000 and the drug you're taking has a very veiled and seemingly dubious cost of $80,000 - does that effect the patient?
I assume it does somewhat directly in the form of higher monthly payments (for the patient and other customers of the insurance)? Can the insurance company deny access due to the high cost?
If this is somewhat the case, I would sort of expect insurance companies to be lobbying for the system to be changed, and they seem to have the capital to actually make a difference in that "fight"?
Maybe I'm misunderstanding something though.. it was an interesting article but it really just gave me even more insight into how confusing the US healthcare system is, even beyond what patients actually interact with.
When it comes to remedies One solution is for our legislature to create laws that specific species some of those practices as illegal. It would probaby be hard to get it passed due to all the corruption in our legislative and executive branches.
I mean there's a spectrum between "acceptable" price discrimination and "abusive". Nobody bats an eye at lower rates for bulk purchases or movie theaters offerering half price for kids.
It may not be a panacea, but sunlight is still a pretty good [civic] disinfectant.
Related
The Opaque Industry Inflating Prices for Prescription Drugs
Pharmacy Benefit Managers (PBMs) like CVS Health, Cigna, and UnitedHealth Group are criticized for increasing prescription drug costs in the US. Despite claims of cost reduction, PBMs allegedly steer towards expensive drugs, charge high markups, and prioritize financial gains over patients. Lawmakers are scrutinizing their practices for potential price inflation and anticompetitive behavior.
FICO and the Credit Bureau Cartel
Mortgage lenders are challenged by a cartel involving major credit bureaus and FICO, leading to rising costs for credit reports and scores. Director Chopra aims to regulate prices, gaining support from affected mortgage bankers.
200 people charged in $2.7B health care fraud crackdown
The Justice Department charged nearly 200 individuals in a $2.7 billion health care fraud crackdown. Cases involved scams targeting terminally ill patients, kickbacks for unnecessary treatments, and assets seized to prevent fleeing.
Pharma firms stash profits in Europe's tax havens
Pharma firms hide €580 billion in European tax havens, affecting drug prices and patient access. Companies exploit tax loopholes, impacting healthcare funding. Calls for transparency and accountability in the pharmaceutical industry arise.
Middlemen have outsized influence on drug prices due to market consolidation,FTC
The FTC highlights PBMs' dominance in U.S. drug pricing. Top PBMs control 79% of claims, raising concerns about cost inflation, lack of transparency, and conflicts of interest. Regulation and scrutiny are needed.